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Abstract: Open-label, matched-case, comparative trial was conducted in 40 HIV-infected patients to evaluate the adjunct 
effect of Dzherelo (Immunoxel) on immune and viral parameters. Arm A (n=20) received anti-retroviral therapy (ART) 
consisting of zidovudine, lamivudine, and efavirenz and arm B (n=20) received ART with Dzherelo. After 2 months total 
T-lymphocytes increased in ART recipients from 664 to 819 cells/μl (P=0.06), whereas in Dzherelo recipients they rose 
from 595 to 785(P=0.03). The CD4 T-cells expanded by 57.3% (218 to 343; P=0.002) in the ART arm and by 93.5% (184 
to 356; P=0.004) in the Dzherelo arm. The accrual in absolute and relative number of CD8+ lymphocytes in ART and in 
the Dzherelo recipients was 43.2% (2.7%) and 50.4% (-0.5%) respectively. The CD4/CD8 ratio in Dzherelo recipients in-
creased from 1.495 to 1.940 (P=0.03) but insignificant in the control: 1.418 to 1.613 (P=0.14). Activated CD3+ HLA-
DR+ T-cells increased from 209 to 264 (P=0.02) and from 161 to 348 (P=0.0007) in ART and Dzherelo recipients respec-
tively. No changes in CD20+ B-lymphocytes were seen in the control, but in Dzherelo patients they declined from 509 to 
333 (P=0.00008). The proportion of CD3- CD16+CD56+ NK cells was not affected by ART but addition of Dzherelo 
raised NK cells from 11.2% to 17.1% (P=0.0001). About three-quarters (14/19) of patients on ART displayed decrease in 
viral load (1718 to 1419 copies/ml; P=0.008), while 95% of patients on Dzherelo had a decrease (1793 to 1368; P=0.001). 
Dzherelo has a favorable effect on the immune status and viral burden when given as an immunomodulating adjunct to 
ART. 
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BACKGROUND 
  Antiretroviral drug resistance, drug toxicity and adher-
ence are major concerns in clinical management of HIV in-
fection [1]. The combination of antiviral drugs, such as 
highly active antiretroviral therapy (HAART), may prevent 
HIV from mutating and spreading, allowing patients to re-
build their immune system to the same levels as in normal 
individuals [2]. On the other hand, the immune activation 
caused by enhanced immune reaction to HIV is now recog-
nized as a cause of depletion of CD4 T-cells and resulting 
immunodeficiency [3]. These problems are a driving force 
for research on new therapies that can provide suitable solu-
tions. The most optimal therapeutic solution is an effective 
and safe immunotherapy that could regulate the immune 
response in a manner favorable to the host. There are many 
types of immune modulators that have been used clinically 
for viral infections, but for HIV the choice of immune inter-
ventions is limited [4]. 
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  Ukraine has the highest prevalence of HIV infection in 
Eastern Europe [5, 6]. Oral immunomodulator Dzherelo is 
used in Ukraine for the management of HIV infections, in-
cluding patients co-infected with TB [7-12]. Clinical studies 
have indicated that Dzherelo can significantly increase CD3 
and CD4 T-lymphocyte populations and helps to achieve 
better clinical response when combined with standard anti-
retroviral therapy (ART) consisting of zidovudine (AZT); 
lamivudine (3TC), and efavirenz (EFV) [7-9]. Dzherelo has 
been found to decrease the incidence of opportunistic infec-
tions and reverse AIDS-associated wasting [7-9]. Dzherelo 
has also been found to decrease the hepatotoxicity associated 
with ART [7-9, 12]. 
  Dzherelo was approved in 1997 by the Ministry of Health 
of Ukraine as an immunomodulating supplement, which so 
far has been used by over 500,000 individuals for various 
indications including chronic bacterial and viral infections 
such as TB and HIV, autoimmune diseases, and malignancy 
[7]. Dzherelo contains concentrated aqueous-alcohol extract 
from medicinal plants such as Aloe, Common knotgrass, 
Yarrow, Purple coneflower, Tutsan, Centaury, Snowball tree 
berries, Nettle, Dandelion, Sweet-sedge, Oregano, Marigold, 
Seabuckthorn fruit, Elecampane, Tormentil, Greater plantain,  
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Wormwood, Siberian golden root, Cottonweed, Licorice, 
Fennel, Birch tree fungus, Thyme, Three-lobe Beggarticks, 
Sage, Dog rose fruit, and Juniper fruit. Our study was aimed 
at evaluating the effect of Dzherelo on immune cell subsets 
and viral load among HIV patients treated with standard 
ART in comparison to a control population which received 
ART alone. 
MATERIALS AND METHODS 
Patients 
  The design of this study is matched case comparative 
study. The patients, aged 20-59 years, have been selected 
and divided into arms A (ART alone) and B (Dzherelo 
added), each consisting of 20 patients matched by their aver-
age initial CD4 counts, gender ratio and age. The average 
(median) age in arms A and B was 33.9 (31.5) and 32.8 (31) 
years. The proportion of males and females was 15/5 and 
17/3 in arms A and B respectively. Patients were in ad-
vanced clinical stage of HIV infection with average baseline 
CD4+ T-cell count being below 200 cells/microliter. Another 
inclusion criterion was the lack of any form of anti-retroviral 
therapy prior to the trial. The diagnosis of HIV infection was 
established by standard ELISA test further confirmed by 
Western blot analysis. The participation in this trial was vol-
untary and patients were enrolled only after signing the writ-
ten consent indicating that they were free to withdraw from 
the study at any time. The conduct of the trial was approved 
by the Ethics board of the AIDS center in compliance with 
the Helsinki declaration. 
Treatment Regimens 
  None of the patients received anti-retroviral therapy prior 
to the trial. After initial screening, qualifying patients were 
randomly divided in two arms: arm A was prescribed: zi-
dovudine (AZT) at 300 mg doses twice-daily; lamivudine 
(3TC) 150 mg tablets twice-daily, and efavirenz (EFV) 600 
mg dose once-daily. The arm B received, in addition to the 
same three-drug ART, twice per day dose of Dzherelo which 
was given as 50 drops diluted in 100 ml of water. 
Immunophenotyping of Lymphocyte Subpopulations 
  The samples of peripheral blood of patients with HIV 
were analyzed using commercially available Clonospectr 
panel of monoclonal antibodies against surface antigens of 
lymphocytes (MedBioSpectr, Moscow, Russia). Assays were 
carried out at study entry and after 1 and 2 months on the 
therapy. The absolute and percent values of the following 
subpopulations were assessed in a blinded fashion by fluo-
rescent microscopy: total T lymphocytes (CD3+); helper T 
lymphocytes (CD3+CD4+); cytotoxic T lymphocytes 
(CD3+CD8+); B lymphocytes (CD20+); natural killer or NK 
cells (CD3-CD16+CD56+); and activated T lymphocytes 
(CD3+HLA-DR+). In addition the changes in the ratio be-
tween CD4 and CD8 cells were evaluated as a part of as-
sessment of the immune status of patients. The samples of 
the blood from 19 healthy blood donors were analyzed as a 
reference for normal values. 
PCR Analysis 
  Stored frozen samples of plasma were processed in bulk 
by using commercially available PCR kit (AmpliSense   
 
HIV-1, Central Research Institute of Epidemiology, Mos-
cow, Russia) designed for quantitative analysis of HIV-RNA 
copies. Tests were carried out at baseline and after two 
months of the therapy. 
Statistical Analysis 
  The obtained results were analyzed with the aid of statis-
tical software STATMOST (Datamost, South Sandy, UT). 
The baseline cell numbers relative to 1st and 2nd months of 
follow-up were evaluated by paired Student t-test. The non-
parametric values such as viral load were analyzed by Wil-
coxon signed-rank test. All statistical calculations were per 
intent-to-treat basis or the total number of available patients 
without subgrouping them into responders and non-
responders. The resulting probability values were considered 
as significant at the cut-off levels of P0.05. 
RESULTS 
  After one month on the therapy there was a clear distinc-
tion between recipients of ART alone and those who re-
ceived ART along with the daily dose of Dzherelo. This dis-
parity became even more evident at the end of 2
nd month of 
therapy. Some but not all immune markers of lymphocyte 
subsets were impacted in a statistically significant manner. 
The changes in viral load among HIV patients of both groups 
also reached statistical significance. These findings are de-
scribed in detail below. 
CD3+ Total T Lymphocytes 
  After one month on ART alone the absolute and percent 
(%) values of total CD3+ lymphocytes per microliter of 
blood changed in a statistically discordant manner i.e. from a 
baseline 664(36.5%) to 743(38.4%) with P=0.13(P=0.03), as 
analyzed by paired Student t-test. Similarly, after one month 
in the group receiving Dzherelo there was a statistical dis-
cordance between absolute and percent CD3+ values: from 
595(34.2%) to 664(40.5%); P=0.14(P=0.0003). After 2 
months the number of total CD3+ lymphocytes increased 
further to 785 (43.9%) in arm B (Dzherelo) i.e. P=0.034 
(P=0.0002), whereas in the control it increased to 819 
(39.8%) cells, with probability values P=0.06 (P=0.03) re-
spectively. The accrual in total lymphocytes from baseline to 
the end of follow-up, was 23.3% and 31.9% for absolute and 
9% and 28.4% for relative numbers in control and Dzherelo 
arms respectively (Fig. 1). 
CD4+ T Lymphocytes 
  The trends similar to those of total CD3+ lymphocytes 
were observed when CD3+CD4+ lymphocyte subsets were 
analyzed. Significant changes were seen in the ART alone 
arm after one month i.e. 218(30.3%) to 295(35.2%); 
P=0.007(P=0.02). Similarly in the Dzherelo arm the helper 
T-cell counts rose in a significant manner from 184(28.4%) 
to 254(34.8%) cells; P=0.03(P=0.0002). At the end of 2
nd 
month lymphocyte subsets rose to 343(35.7%) and 356(38%) 
with probability values P=0.002(P=0.01) and P=0.004 
(P=0.0005) for arms A and B respectively. When study 
completion results of ART and Dzherelo recipients were 
calculated in terms of accrual in CD4+ lymphocytes relative 
to entry levels there was an increase of 57.3%(17.8%) and 
93.5%(33.8%) in absolute and relative values. 
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CD8+ T Lymphocytes 
  The changes observed in CD3+CD8+ cytotoxic T-cell 
population are different from those seen with helper cells. In 
the ART alone group, absolute but not relative numbers of 
CD8+ cells increased in a significant manner from 
155(22.6%) to 203(24%); P=0.014 (P=0.21), while in the 
Dzherelo group the changes were insignificant in both cate-
gories i.e. from 123(19.8%) to 152(20.3%); P=0.08(P=0.28). 
At the end of the 2
nd month the CTL population in the ART 
group was still above baseline i.e. 222 cells (23.2%), an ac-
crual that was statistically significant for absolute numbers 
P=0.009 but not significant when relative numbers were 
evaluated (P=0.39). Similarly, among Dzherelo recipients 
the 2
nd month absolute but not relative numbers of CD8 cells 
also increased in a significant manner, from baseline levels 
123(19.8%) to 185(19.7%), with P values being 0.013 and 
0.39 respectively. When study completion results of ART 
and Dzherelo recipients were calculated in terms of accrual 
in CD8+ lymphocytes as compared to baseline levels there 
was an accrual corresponding to 43.2%(2.7%) and 50.4%(-
0.5%) of absolute and relative values respectively. 
CD4/CD8 Ratio 
  The differential changes in CD4 and CD8 lymphocyte 
numbers affected the CD4/CD8 ratio in patients on ART 
alone regimen as early as one month after treatment initia-
tion. The ratio increased from baseline value 1.418 to 1.532 
but without reaching significance (P=0.23). The CD4/CD8 
ratio among Dzherelo recipients increased from 1.495 to 
1.671, which was also above the cut-off value (P=0.09). The 
disparity between CD4 and CD8 lymphocytes had pro-
gressed further by the end of 2
nd month. Among the ART 
alone patients the ratio increased to 1.613(P=0.14), while in 
Dzherelo group the ratio rose to 1.940 (P=0.03). When study 
end results of ART and Dzherelo recipients were calculated 
in terms of relative accrual from baseline levels there was a 
gain of 13.8% and 29.3% respectively. 
CD3+HLA-DR+ Activated Lymphocytes 
  The absolute and percent numbers of activated 
CD3+HLA-DR+ T cells increased steadily in ART group 
from 209 (24.7%) to 231 (26.6%), and then to 264 (27.8%) 
with P=0.13(P=0.04) and P=0.02(P=0.02) at the end of first 
and second months respectively. In Dzherelo recipients this 
subpopulation increased at higher incremental rate from 
161(25.9%) to 247(35.1%) and then to 348(36.5%) with 
P=0.01(P=0.0004) and P=0.0007(P=0.0003) respectively. 
The relative accrual in absolute and relative numbers in ART 
group was 26.3%(12.6%) at the end of the 2
nd month. During 
the same time period the patients who received Dzherelo 
experienced 216%(40.9%) increase over baseline in absolute 
and relative numbers respectively. 
CD20+ B Lymphocytes 
  In patients who received ART alone B-cell counts moved 
up slightly but differences were not statistically significant at 
either time point. At the end of the 1
st month they rose from 
522 (28.3%) to 526 (28.2%) cells P=0.43 (P=0.37) and at 
study conclusion they reached 542 (27.3%); P=0.47 
(P=0.22). However, patients who received Dzherelo dis-
played a significant decrease in CD20+ lymphocyte num-
bers. The entry value of 509 (31%) cells went down to 367 
(24.9%) at the 1
st month and then to 333 (23.3%) toward end 
of the study with probability values P=0.003 (P=0.0002) and 
P=0.00008 (P=0.00002) respectively. At this time point the 
number of CD20-expressing cells became indistinguishable 
from the value of normal donors i.e. 337 cells (22.2%). 
CD3-CD16+CD56+ NK Cells 
  The relative numbers of NK cells identified as CD3-
negative but CD16+CD56+ population were not significantly 
affected by ART alone therapy: from baseline level of 19.3% 
they rose to 21.2% (P=0.17), and then to 22.3% at study 
conclusion (P=0.12). The addition of daily dose of Dzherelo, 
however, had a strong effect on gain of NK cells. The   
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Fig. (1). Changes in absolute and relative numbers of peripheral blood cell subpopulations at 2 months post-therapy as expressed in percent-
age values (Y-axis) relative to their respective baseline levels. 34    The Open Virology Journal, 2009, Volume 3  Nikolaeva et al. 
patients who started with an average 11.2% NK cells had 
their numbers increased to 13.7% (P=0.004), which further 
increased to 17.1% (P=0.0001). Thus, at the end of 2-month 
of therapy, the patients on Dzherelo had experienced 52.7% 
increase in NK cells as compared to baseline levels. 
Lymphocyte Subsets in Normal Blood Donors 
  Samples of the peripheral blood of 19 healthy individuals 
were analyzed to obtain the normal distribution values of 
peripheral blood subsets. The average number of absolute 
and relative (%) CD3 lymphocytes were 1,370±169 cells/μl 
(52.9±6.8). The values of CD4 and CD8 lymphocytes were 
622±89 (35.9±4.3) and 349±42 (19.9±2.1) respectively, with 
the ratio being 1.76±0.19. The HLA-DR+ expressing acti-
vated T-cells represented 585±131 cells (35.2±3.5). The ab-
solute and percent figures of CD20+ B-lymphocytes per μl 
of blood were 337±52 (22.2±4.3). The percentage of NK 
cells was 12.2±2.9%. 
Viral Load 
  The viral load, as measured by plasma RNA-PCR at 
baseline and at the end of 2
nd month, decreased in the ART 
group (1718 to 1419 copies/ml; P=0.008), as analyzed by 
Wilcoxon signed rank test. In the Dzherelo arm the viral load 
decreased from 1793 to 1368 copies; P=0.001). About three-
quarters (14/19) of patients on ART alone displayed the de-
crease in viral load, while 18 out of 19 of patients on 
Dzherelo (95%) had a reduction in their number of viral cop-
ies (Table 1). 
DISCUSSION 
  In prior studies Dzherelo has been shown to influence 
positively CD3 and CD4 lymphocyte numbers [7-9]. 
Dzherelo reduced the incidence of opportunistic infections 
and reversed body weight loss associated with HIV [7, 10]. It 
has also been shown to reduce the toxic side effects of ART, 
hepatotoxicity in particular [7, 9, 12]. For example, elevated 
liver aminopeptidase ALT and AST levels caused by ART 
have been shown to return back to normal levels when 
Dzherelo is used. However, these studies have not dealt with 
the effect of Dzherelo on other immune markers and viral 
load. 
  Our 2-month study conducted in prior anti-retroviral 
drug-naïve population reveals that when Dzherelo is added 
to ART there are significant benefits associated with this 
Table 1.  Effect of 2-Month ART without or with Dzherelo on HIV-RNA Plasma Levels 
 
Arm A 
HIV Patients on ART Alone (N=20) 
Arm B 
HIV Patients on ART + Dzherelo (N=20) 
Patient 
No.  HIV-RNA Copies/ml 
at Baseline 
HIV-RNA Copies/ml 
at 2
nd Month 
Difference Com-
pared to Baseline 
HIV-RNA Copies/ml 
at Baseline 
HIV-RNA  
Copies/ml at 2
nd 
Month 
Difference 
Compared to 
Baseline 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
847.2 
1756.8 
978.1 
2564.3 
345.4 
2053.0 
763.2 
1537.0 
894.2 
7442.1 
346.4 
3178.2 
237.0 
881.3 
1045.0 
2339.3 
473.1 
3088.2 
ND 
1865.5 
473.5 
1308.3 
1123.6 
1141.2 
96.1 
1845.1 
1295.1 
867.1 
778.0 
7601.4 
189.3 
2723.1 
91.3 
922.4 
851.1 
1911.0 
529.4 
2064.3 
ND 
1141.1 
-373.7 
-448.5 
+145.5 
-1423.1 
-249.3 
-207.9 
+531.9 
-669.9 
-116.2 
+159.3 
-157.1 
-455.1 
-145.7 
+41.1 
-193.9 
-428.3 
+56.3 
-1023.9 
ND 
-724.4 
952.2 
1353.0 
ND 
3899.1 
818.4 
1938.0 
2501.4 
783.5 
464.3 
937.3 
1558.1 
10136.5 
539.0 
669.4 
1749.4 
973.6 
889.7 
2377.1 
254.5 
1271.3 
421.2 
789.1 
ND 
1854.4 
379.1 
956.3 
2296.1 
1394.6 
235.1 
562.1 
1415.4 
10112.1 
241.3 
314.2 
958.2 
689.1 
564.2 
1918.4 
99.4 
788.3 
-531 
-563.9 
ND 
-2044.7 
-439.3 
-981.7 
-205.3 
+611.1 
-229.2 
-375.2 
-142.7 
-24.4 
-297.7 
-355.2 
-791.2 
-284.5 
-325.5 
-458.7 
-155.1 
-483 
Statistics  Mean±SD= 
1717±1660 
Geometric mean=1199 
Median=1045 
Mean±SD= 
1419±1650 
Geometric mean=876 
Median=1124 
Mean±SD= 
-299±448 
Geometric 
mean=272 
Median=208 
Wilcoxon signed 
rank test; P=0.008 
Mean±SD= 
1792±2202 
Geometric 
mean=1222 
Median=974 
Mean±SD= 
1368±2208 
Geometric 
mean=762 
Median=788 
Mean±SD= 
-425±507 
Geometric 
mean=353 
Median= 
-355 
Wilcoxon 
signed rank 
test; P=0.001 
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intervention. In our hands Dzherelo appears to display the 
same effect as reported by independent investigators. Our 
results indicate that administration of Dzherelo along with 
ART can produce significant increase in total CD3+ lym-
phocytes, CD4+ helper cells, better CD4/CD8 ratio, higher 
number of CD3+HLA-DR+ activated lymphocytes, and NK 
cells. Dzherelo appears to increase absolute but not relative 
numbers of CD8+ T lymphocytes and reduce significantly 
CD20+ B lymphocyte subpopulation. Furthermore, Dzherelo 
appears to contribute to the inhibitory effect of ART on viral 
replication resulting in statistically significant lower viral 
load in a higher proportion of patients (Table 1). These ef-
fects could not be attributed to heterogeneity of patient popu-
lations in two tightly matched treatment groups in which 
none of the initial characteristics in terms of age, gender, 
disease stage and cell counts were statistically different at 
baseline. 
  It is well established that elevated CD3 and CD4 counts 
and higher CD4/CD8 ratio are associated with better progno-
sis in patients with HIV [13]. For this reason Dzherelo is 
likely to influence positively the outcome of treatment and 
disease progression in our study population. Similarly, viral 
load is a predictor of HIV disease progression, its persistent 
elevation in HIV infected patients being indicative of poor 
prognosis [14, 15]. While there were earlier indications that 
Dzherelo may reduce the viral burden, our study is the first 
to report this phenomenon in a systematic fashion. Despite 
the fact that the HIV RNA levels had decreased by less than 
a log the difference between baseline and outcome levels 
was highly significant (Table 1). While baseline and out-
come viral burden appeared unusually low, this may have 
been due to the PCR kit we have used in this study; since we 
have seen similar low numbers in our study dealing with 
TB/HIV dually infected patients [10]. Nevertheless, it is 
likely that the observed effect on viral load is mediated by 
immune cells since Dzherelo does not have a direct effect on 
HIV replication [7]. 
  Our study reveals that at the end of study the patients on 
Dzherelo had absolute and relative numbers of CD3+HLA-
DR+ cells equal to 348 (36.5%) or 216% and 40.9% more 
compared to baseline, whereas patients on ART had their 
numbers increased to a maximum 26.3%. Compared to nor-
mal blood donors the relative numbers in Dzherelo group 
were comparable but absolute values were lower i.e. 35.2% 
and 585 respectively. It has been shown that HIV+ patients 
usually have significantly higher HLA-DR expressing cells, 
which may negatively affect T cell immune responses and 
facilitate the disease progression [16]. Others suggested that 
the increase in HLA-DR-reactive T lymphocytes was not 
predictive of clinical outcome [17]. We do not know to 
which subpopulation of T lymphocytes the CD3+HLA-DR+ 
activated cells belong. Judging from relative changes in CD4 
and CD8 subsets it is possible that the activation marker is 
expressed on CD4 cells. However, due to limitations of the 
commercially available panel of antibodies preventing simul-
taneous staining with multiple fluorescent markers, we have 
not been able to verify this possibility. This needs to be as-
certained in future studies. 
  Although a great deal of information is available about 
the role of T lymphocytes in the immune response against 
HIV comparatively little is understood regarding the in-
volvement of B lymphocytes. Our results show very little 
variation in CD20+ B-cell numbers in the ART-treated arm 
but a highly significant decrease in Dzherelo recipients to 
levels that were identical to those seen in normal individuals 
i.e. 333 (23.3%) vs 337 (22.2%). Contrarily, the absolute and 
relative numbers of B-cells were more than double in ART 
recipients. We do not know what the significance of this 
observation is. It has been reported that the expression of 
CD20 is consistently higher when B cells from HIV-infected 
individuals are compared with those from uninfected sub-
jects [18]. Thus, we can only assert that Dzherelo is highly 
effective in restoring the normal balance of CD20 expressing 
B-cells. 
  We have observed the drastic difference between two 
arms in relative number of NK cells after 2 months of ther-
apy. When compared to the entry levels the patients on 
Dzherelo had 52.7% more of NK cells whereas the popula-
tion of these cells had increased by only 15.5% in ART alone 
group. The role of NK cells in HIV remains unclear. While 
some indicated that higher number of NK cells is critical for 
controlling HIV, others indicated that the quality but not the 
number of cells is critical in defending the host against HIV 
infection [19, 20]. This discrepancy probably stems from 
differences in the design of studies some of which were 
based on measurement of functional activity but others were 
based on the enumeration of cells at various stages of the 
disease. Since we have not measured the functional activity 
of NK cells we do not know what is the significance of this 
phenomenon in regard to the immunopathogenesis of HIV. 
Based on the evidence that Dzherelo is highly effective as an 
immune adjuvant to ART we can only speculate that in our 
case the increase in NK numbers might be beneficial to the 
host. 
  Many studies have been conducted aimed at determining 
the phenotype of immune cells in HIV infection. While there 
is a consensus that the immune response plays a critical role 
in determining the clinical outcome much more has to be 
learned in order to have a clear picture of cellular events 
during the course of disease. The understanding of the im-
mune mechanism controlling HIV may result in design of 
better vaccines and immunotherapies. Therefore, high prior-
ity should be given to efforts of prevention and treatment of 
infectious complications in these patients. 
  Currently available chemotherapy for the treatment of 
HIV is not ideal, requiring multiple drugs to be taken in 
combination for the rest of life of a patient [1]. The extended 
duration of therapy, coupled with the side effects, often re-
sults in poor patient adherence, treatment failure, and the 
emergence of drug resistance with major social and eco-
nomic implications. We believe that immunotherapy is an 
indispensable part of therapeutic strategies against HIV. The 
development of novel immune-based therapies is an urgent 
objective for anti-HIV drug discovery. Many immune inter-
ventions are available against bacteria, protozoa, fungi and 
viruses. While often effective the mechanism of many im-
munomodulators is poorly understood. This downside should 
be balanced against clinically confirmed benefits. Our study 
provides an early glimpse into the putative immune mecha-
nism of Dzherelo, which has been successfully used as an 
immune adjunct to HIV therapy in Ukraine during last ten 
years [7-12]. Additional studies are needed to develop better 36    The Open Virology Journal, 2009, Volume 3  Nikolaeva et al. 
understanding of Dzherelo’s properties and to supplement 
the current arsenal of HIV therapies. 
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ABBREVIATIONS 
ART =  Antiretroviral  therapy 
EFV =  Efavirenz 
HAART  =  Highly active antiretroviral therapy 
HLA  =  Human leukocyte antigen 
3TC =  Lamivudine 
NK =  Natural  killer 
PCR  =  Polymerase chain reaction 
RNA =  Ribonucleic  acid 
TB =  Tuberculosis 
AZT =  Zidovudine 
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